Incidence of long COVID among U.S. children and adults during the omicron era – Tracking Post-COVID Conditions (Track-PCC) network, 2022–2023

IF 4 3区医学 Q1 INFECTIOUS DISEASES

Journal of Infection and Public Health Pub Date : 2025-08-26 DOI:10.1016/j.jiph.2025.102935

Brian E. Dixon , Katie S. Allen , Nicole Simmons , Jason Brinkley , Jennifer G. Andrews , Bari J. Dzomba , Marina O. Feiler , Resa M. Jones , Miguel Reina Ortiz , Vinita Sharma , Alexandra F. Dalton , Caroline Pratt , Shaun J. Grannis , Sharon H. Saydah , for the Track PCC Study Group

{"title":"Incidence of long COVID among U.S. children and adults during the omicron era – Tracking Post-COVID Conditions (Track-PCC) network, 2022–2023","authors":"Brian E. Dixon , Katie S. Allen , Nicole Simmons , Jason Brinkley , Jennifer G. Andrews , Bari J. Dzomba , Marina O. Feiler , Resa M. Jones , Miguel Reina Ortiz , Vinita Sharma , Alexandra F. Dalton , Caroline Pratt , Shaun J. Grannis , Sharon H. Saydah , for the Track PCC Study Group","doi":"10.1016/j.jiph.2025.102935","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Long COVID, or Post-COVID Conditions (PCC), refers to new and persisting sequelae occurring in the months following an acute SARS-CoV-2 infection. Although previous studies have reported estimates of PCC incidence, few have examined trends during the Omicron variant period or have included geographically distinct regions for the same time periods.</div></div><div><h3>Methods</h3><div>Track PCC is a surveillance network, leveraging electronic health records and public health data to monitor incidence over time across five diverse geographic sites in the U.S. This study examines the incidence of PCC in children and adults during the Omicron predominance period (January 1, 2022, to December 31, 2023) through April 2024. Incident conditions were identified using diagnostic codes for 49 conditions. Crude and adjusted incidence for the occurrence of PCC per 1000 person-days was calculated independently during three post-acute time periods: 31–90 days, 91–180 days, and 181–365 days. Incidence of PCC per 1000 person-days was also calculated by demographic and clinical characteristics.</div></div><div><h3>Results</h3><div>The Track PCC network included 438,491 adults and 85,264 children with COVID-19 during the Omicron period. PCC incidence was highest 31–90 days post-acute; range from 2.95 to 5.05 per 1000 person-days among adults and 1.53–3.15 per 1000 person-days among children. Incidence was higher among older patients and patients with 3 or more co-morbidities and generally stable across variant sublineage periods.</div></div><div><h3>Conclusion</h3><div>These data suggest the PCC incidence following acute COVID-19 has not increased during the Omicron period. This is useful for understanding the burden of PCC and estimating demand of medical services following acute COVID-19 infections. PCC surveillance, including tracking the incidence of PCC, understanding patients at higher likelihood of developing PCC, and creating robust estimates, is critical to public health efforts to understand disease burden and guide prevention and treatment efforts.</div></div>","PeriodicalId":16087,"journal":{"name":"Journal of Infection and Public Health","volume":"18 11","pages":"Article 102935"},"PeriodicalIF":4.0000,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Infection and Public Health","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1876034125002849","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Long COVID, or Post-COVID Conditions (PCC), refers to new and persisting sequelae occurring in the months following an acute SARS-CoV-2 infection. Although previous studies have reported estimates of PCC incidence, few have examined trends during the Omicron variant period or have included geographically distinct regions for the same time periods.

Methods

Track PCC is a surveillance network, leveraging electronic health records and public health data to monitor incidence over time across five diverse geographic sites in the U.S. This study examines the incidence of PCC in children and adults during the Omicron predominance period (January 1, 2022, to December 31, 2023) through April 2024. Incident conditions were identified using diagnostic codes for 49 conditions. Crude and adjusted incidence for the occurrence of PCC per 1000 person-days was calculated independently during three post-acute time periods: 31–90 days, 91–180 days, and 181–365 days. Incidence of PCC per 1000 person-days was also calculated by demographic and clinical characteristics.

Results

The Track PCC network included 438,491 adults and 85,264 children with COVID-19 during the Omicron period. PCC incidence was highest 31–90 days post-acute; range from 2.95 to 5.05 per 1000 person-days among adults and 1.53–3.15 per 1000 person-days among children. Incidence was higher among older patients and patients with 3 or more co-morbidities and generally stable across variant sublineage periods.

Conclusion

These data suggest the PCC incidence following acute COVID-19 has not increased during the Omicron period. This is useful for understanding the burden of PCC and estimating demand of medical services following acute COVID-19 infections. PCC surveillance, including tracking the incidence of PCC, understanding patients at higher likelihood of developing PCC, and creating robust estimates, is critical to public health efforts to understand disease burden and guide prevention and treatment efforts.

查看原文本刊更多论文

2022-2023年美国儿童和成人长冠状病毒发病率-追踪后冠状病毒状况（Track-PCC）网络

长冠状病毒或后冠状病毒（PCC）是指急性SARS-CoV-2感染后几个月内出现的新的和持续的后遗症。虽然以前的研究报告了对PCC发病率的估计，但很少有研究检查了在欧米克隆变异时期的趋势，或者在同一时期包括地理上不同的区域。strack PCC是一个监测网络，利用电子健康记录和公共卫生数据监测美国五个不同地理站点的PCC发病率。本研究调查了Omicron优势期（2022年1月1日至2023年12月31日）至2024年4月期间儿童和成人PCC的发病率。使用49种情况的诊断代码确定了事件条件。在急性期后的三个时间段：31-90天、91-180天和181-365天，独立计算每1000人天PCC发生的粗发生率和调整发生率。根据人口学和临床特征计算每1000人日的PCC发病率。结果Track PCC网络包括在Omicron期间感染COVID-19的438,491名成人和85,264名儿童。急性后31 ~ 90 d PCC发病率最高；成人每1000人日2.95 - 5.05人，儿童每1000人日1.53-3.15人。老年患者和有3种或更多合并症的患者发病率较高，在不同亚谱系期总体稳定。结论急性COVID-19后PCC的发病率在Omicron期间没有增加。这有助于了解PCC负担和估计COVID-19急性感染后的医疗服务需求。对PCC的监测，包括跟踪PCC的发病率，了解发生PCC的可能性较高的患者，并建立可靠的估计，对于了解疾病负担和指导预防和治疗工作的公共卫生工作至关重要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Infection and Public Health PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH -INFECTIOUS DISEASES

CiteScore

13.10

自引率

1.50%

发文量

203

审稿时长

96 days

期刊介绍： The Journal of Infection and Public Health, first official journal of the Saudi Arabian Ministry of National Guard Health Affairs, King Saud Bin Abdulaziz University for Health Sciences and the Saudi Association for Public Health, aims to be the foremost scientific, peer-reviewed journal encompassing infection prevention and control, microbiology, infectious diseases, public health and the application of healthcare epidemiology to the evaluation of health outcomes. The point of view of the journal is that infection and public health are closely intertwined and that advances in one area will have positive consequences on the other. The journal will be useful to all health professionals who are partners in the management of patients with communicable diseases, keeping them up to date. The journal is proud to have an international and diverse editorial board that will assist and facilitate the publication of articles that reflect a global view on infection control and public health, as well as emphasizing our focus on supporting the needs of public health practitioners. It is our aim to improve healthcare by reducing risk of infection and related adverse outcomes by critical review, selection, and dissemination of new and relevant information in the field of infection control, public health and infectious diseases in all healthcare settings and the community.